{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sacubitril%2FValsartan",
    "query": {
      "intervention": "Sacubitril/Valsartan"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sacubitril%2FValsartan&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T20:58:01.894Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02816736",
      "title": "EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "LCZ696",
          "type": "DRUG"
        },
        {
          "name": "valsartan",
          "type": "DRUG"
        },
        {
          "name": "LCZ696 placebo",
          "type": "DRUG"
        },
        {
          "name": "valsartan placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 365,
      "start_date": "2017-03-02",
      "completion_date": "2020-09-29",
      "has_results": true,
      "last_update_posted_date": "2021-12-03",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 38,
      "location_summary": "Beverly Hills, California • Sacramento, California • San Diego, California + 28 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02816736"
    },
    {
      "nct_id": "NCT03387163",
      "title": "Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure, Systolic"
      ],
      "interventions": [
        {
          "name": "Sacubitril/Valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2018-02-09",
      "completion_date": "2019-06-21",
      "has_results": false,
      "last_update_posted_date": "2019-12-13",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03387163"
    },
    {
      "nct_id": "NCT05848206",
      "title": "Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Heart Failure"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 251831,
      "start_date": "2022-03-11",
      "completion_date": "2022-04-29",
      "has_results": false,
      "last_update_posted_date": "2023-05-08",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05848206"
    },
    {
      "nct_id": "NCT03744975",
      "title": "PDD in Type 2 Diabetes w/wo Diastolic Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Diastolic Dysfunction"
      ],
      "interventions": [
        {
          "name": "LCZ 696",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2018-05-01",
      "completion_date": "2025-08-27",
      "has_results": false,
      "last_update_posted_date": "2025-12-12",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03744975"
    },
    {
      "nct_id": "NCT03005184",
      "title": "Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure NYHA Class I",
        "Heart Failure NYHA Class II",
        "Heart Failure NYHA Class III"
      ],
      "interventions": [
        {
          "name": "Valsartan 80 mg bid",
          "type": "DRUG"
        },
        {
          "name": "Enalapril 10 mg bid",
          "type": "DRUG"
        },
        {
          "name": "Sacubitril-Valsartan 200 mg bid",
          "type": "DRUG"
        },
        {
          "name": "Icatibant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-09",
      "completion_date": "2020-01",
      "has_results": false,
      "last_update_posted_date": "2018-01-11",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03005184"
    },
    {
      "nct_id": "NCT03938389",
      "title": "The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "PreDiabetes",
        "Impaired Glucose Tolerance",
        "Obesity",
        "Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Sacubitril-Valsartan Tab 97-103 MG",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2020-02-25",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03938389"
    },
    {
      "nct_id": "NCT02788656",
      "title": "Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Implantable Hemodynamic Monitor",
          "type": "DEVICE"
        },
        {
          "name": "Angiotensin-Converting Enzyme Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin II Type 1 Receptor Blocker",
          "type": "DRUG"
        },
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-09",
      "completion_date": "2018-11-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788656"
    },
    {
      "nct_id": "NCT02970669",
      "title": "Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure, Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan (LCZ696)",
          "type": "DRUG"
        },
        {
          "name": "enalapril",
          "type": "DRUG"
        },
        {
          "name": "matching placebo sacubitril/valsartan (LCZ696)",
          "type": "DRUG"
        },
        {
          "name": "matching placebo enalapril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 140,
      "start_date": "2016-12-16",
      "completion_date": "2018-03-19",
      "has_results": true,
      "last_update_posted_date": "2021-10-07",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 23,
      "location_summary": "Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more",
      "locations": [
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "West Hills",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02970669"
    },
    {
      "nct_id": "NCT05613140",
      "title": "Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Heart Failure"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 9230,
      "start_date": "2021-08-02",
      "completion_date": "2021-11-05",
      "has_results": false,
      "last_update_posted_date": "2022-11-15",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05613140"
    },
    {
      "nct_id": "NCT05498181",
      "title": "Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Sacubitril-valsartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2022-10-11",
      "completion_date": "2026-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-09-23T20:58:01.894Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05498181"
    }
  ]
}